Drugs / Human Placenta-derived 3D Mesenchymal Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07635758 | Jun 2026 → Dec 2027 expected | ischemic stroke | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Placenta-derived 3D Mesenchymal Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07635758 ↗ |
| Known as | Guojiangqingke | “Human Placenta-derived 3D Mesenchymal Stem Cells (Guojiangqingke)” NCT07635758 ↗ |
| Modality | Cell therapy | “human placental-derived 3D MSC injection” NCT07635758 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07635758 ↗ |